Chronic Macrolide Therapy in Inflammatory Airways Diseases

被引:115
作者
Friedlander, Adam L. [1 ,2 ]
Albert, Richard K. [2 ,3 ]
机构
[1] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA
[2] Denver Hlth, Div Pulm Sci & Crit Care Med, Denver, CO USA
[3] Denver Hlth, Dept Med, Denver, CO USA
关键词
BRONCHIOLITIS-OBLITERANS-SYNDROME; OBSTRUCTIVE PULMONARY-DISEASE; LONG-TERM AZITHROMYCIN; FACTOR-KAPPA-B; NECROSIS-FACTOR-ALPHA; PSEUDOMONAS-AERUGINOSA; CYSTIC-FIBROSIS; IN-VITRO; BRONCHIAL HYPERRESPONSIVENESS; MAINTENANCE AZITHROMYCIN;
D O I
10.1378/chest.10-0196
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Long-term therapy with the macrolide antibiotic erythromycin was shown to alter the clinical course of diffuse panbronchiolitis in the late 1980s. Since that time, macrolides have been found to have a large number of antiinflammatory properties in addition to being antimicrobials. These observations provided the rationale for many studies performed over the last decade to assess the usefulness of macrolides in other inflammatory airways diseases, such as cystic fibrosis, asthma, COPD, and bronchiolitis obliterans syndrome. This review summarizes the immunomodulatory properties of macrolides and the results of these recent studies demonstrating their potential for being disease-modifying agents. CHEST 2010; 138(5):1202-1212
引用
收藏
页码:1202 / 1212
页数:11
相关论文
共 99 条
[1]  
Abdelghaffar H, 1997, J IMMUNOL, V159, P3995
[2]   Update in cystic fibrosis 2007 [J].
Accurso, Frank J. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (10) :1058-1061
[3]   Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants [J].
Aghai, Zubair H. ;
Kode, Aruna ;
Saslow, Judy G. ;
Nakhla, Tarek ;
Farhath, Sabeena ;
Stahl, Gary E. ;
Eydelman, Riva ;
Strande, Louise ;
Leone, Paola ;
Rahman, Irfan .
PEDIATRIC RESEARCH, 2007, 62 (04) :483-488
[4]   Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma [J].
Amayasu, H ;
Yoshida, S ;
Ebana, S ;
Yamamoto, Y ;
Nishikawa, T ;
Shoji, T ;
Nakagawa, H ;
Hasegawa, H ;
Nakabayashi, M ;
Ishizaki, Y .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2000, 84 (06) :594-598
[5]   Bronchial inflammation and colonization in patients with clinically stable bronchiectasis [J].
Angrill, J ;
Agustí, C ;
De Celis, R ;
Filella, X ;
Rañó, A ;
Elena, M ;
De la Bellacasa, JP ;
Xaubet, A ;
Torres, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (09) :1628-1632
[6]  
Banerjee Dev, 2004, Treat Respir Med, V3, P59, DOI 10.2165/00151829-200403010-00007
[7]   Medical progress - Bronchiectasis [J].
Barker, AF .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (18) :1383-1393
[8]   Emerging Pharmacotherapies for COPD [J].
Barnes, Peter J. .
CHEST, 2008, 134 (06) :1278-1286
[9]   The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: Preliminary data [J].
Basyigit, I ;
Yildiz, F ;
Ozkara, SK ;
Yildirim, E ;
Boyaci, H ;
Ilgazli, A .
ANNALS OF PHARMACOTHERAPY, 2004, 38 (09) :1400-1405
[10]   Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin [J].
Baumann, U ;
Fischer, JJ ;
Gudowius, P ;
Lingner, M ;
Herrmann, S ;
Tümmler, B ;
von der Hardt, H .
INFECTION, 2001, 29 (01) :7-11